These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

886 related articles for article (PubMed ID: 33216972)

  • 41. [CAR-T cells immunotherapy in multiple myeloma: Present and future].
    Ferment B; Arnulf B
    Bull Cancer; 2021 Oct; 108(10S):S65-S72. PubMed ID: 34920809
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Monoclonal Antibodies: The Greatest Resource to Treat Multiple Myeloma.
    De Luca F; Allegra A; Di Chio C; Previti S; Zappalà M; Ettari R
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834545
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myeloma.
    Wang D; Wang J; Hu G; Wang W; Xiao Y; Cai H; Jiang L; Meng L; Yang Y; Zhou X; Hong Z; Yao Z; Xiao M; Chen L; Mao X; Zhu L; Wang J; Qiu L; Li C; Zhou J
    Blood; 2021 May; 137(21):2890-2901. PubMed ID: 33512480
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Recent updates on CAR T clinical trials for multiple myeloma.
    Lin Q; Zhao J; Song Y; Liu D
    Mol Cancer; 2019 Nov; 18(1):154. PubMed ID: 31684964
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: latest updates from ASCO 2023 Annual Meeting.
    Zhao J; Ren Q; Liu X; Guo X; Song Y
    J Hematol Oncol; 2023 Aug; 16(1):92. PubMed ID: 37537597
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Novel therapies for multiple myeloma].
    Ri M
    Rinsho Ketsueki; 2024; 65(6):547-557. PubMed ID: 38960655
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Quad-class exposed/refractory myeloma is associated with short survival.
    Piron B; Costes-Tertrais D; Gastinne T; Fourmont AM; Dubruille V; Blin N; Moreau P; Touzeau C; Tessoulin B
    Br J Haematol; 2024 Jan; 204(1):186-190. PubMed ID: 37833834
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of infectious complications with BCMA-directed therapies in multiple myeloma.
    Nath K; Shekarkhand T; Nemirovsky D; Derkach A; Costa BA; Nishimura N; Farzana T; Rueda C; Chung DJ; Landau HJ; Lahoud OB; Scordo M; Shah GL; Hassoun H; Maclachlan K; Korde N; Shah UA; Tan CR; Hultcrantz M; Giralt SA; Usmani SZ; Shahid Z; Mailankody S; Lesokhin AM
    Blood Cancer J; 2024 May; 14(1):88. PubMed ID: 38821925
    [TBL] [Abstract][Full Text] [Related]  

  • 49. B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma.
    Cohen AD; Garfall AL; Stadtmauer EA; Melenhorst JJ; Lacey SF; Lancaster E; Vogl DT; Weiss BM; Dengel K; Nelson A; Plesa G; Chen F; Davis MM; Hwang WT; Young RM; Brogdon JL; Isaacs R; Pruteanu-Malinici I; Siegel DL; Levine BL; June CH; Milone MC
    J Clin Invest; 2019 Mar; 129(6):2210-2221. PubMed ID: 30896447
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma.
    Panowski SH; Kuo TC; Zhang Y; Chen A; Geng T; Aschenbrenner L; Kamperschroer C; Pascua E; Chen W; Delaria K; Farias S; Bateman M; Dushin RG; Chin SM; Van Blarcom TJ; Yeung YA; Lindquist KC; Chunyk AG; Kuang B; Han B; Mirsky M; Pardo I; Buetow B; Martin TG; Wolf JL; Shelton D; Rajpal A; Strop P; Chaparro-Riggers J; Sasu BJ
    Mol Cancer Ther; 2019 Nov; 18(11):2008-2020. PubMed ID: 31434693
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Bispecific Antibodies for Multiple Myeloma: A Review of Targets, Drugs, Clinical Trials, and Future Directions.
    Caraccio C; Krishna S; Phillips DJ; Schürch CM
    Front Immunol; 2020; 11():501. PubMed ID: 32391000
    [TBL] [Abstract][Full Text] [Related]  

  • 52. BCMA-targeted therapies for multiple myeloma: strategies to maximize efficacy and minimize adverse events.
    Watson E; Djebbari F; Rampotas A; Ramasamy K
    Expert Rev Hematol; 2022 Jun; 15(6):503-517. PubMed ID: 35633050
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma.
    Xu J; Chen LJ; Yang SS; Sun Y; Wu W; Liu YF; Xu J; Zhuang Y; Zhang W; Weng XQ; Wu J; Wang Y; Wang J; Yan H; Xu WB; Jiang H; Du J; Ding XY; Li B; Li JM; Fu WJ; Zhu J; Zhu L; Chen Z; Fan XF; Hou J; Li JY; Mi JQ; Chen SJ
    Proc Natl Acad Sci U S A; 2019 May; 116(19):9543-9551. PubMed ID: 30988175
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Integrating Immune Therapies for the Treatment of Multiple Myeloma.
    Mikkilineni L; Sidana S
    J Natl Compr Canc Netw; 2023 Dec; 21(12):1303-1311. PubMed ID: 38081142
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Preclinical discovery and initial clinical data of WVT078, a BCMA × CD3 bispecific antibody.
    Raab MS; Cohen YC; Schjesvold F; Aardalen K; Oka A; Spencer A; Wermke M; Souza AD; Kaufman JL; Cafro AM; Ocio EM; Doki N; Henson K; Trabucco G; Carrion A; Bender FC; Juif PE; Fessehatsion A; Fan L; Stonehouse JP; Blankenship JW; Granda B; De Vita S; Lu H
    Leukemia; 2023 Jun; 37(6):1349-1360. PubMed ID: 37024520
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy of Humanized Anti-BCMA CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With and Without Extramedullary Disease.
    Deng H; Liu M; Yuan T; Zhang H; Cui R; Li J; Yuan J; Wang X; Wang Y; Deng Q
    Front Immunol; 2021; 12():720571. PubMed ID: 34421924
    [TBL] [Abstract][Full Text] [Related]  

  • 57. BCMA loss in the epoch of novel immunotherapy for multiple myeloma: from biology to clinical practice.
    Zhou X; Rasche L; Kortüm KM; Mersi J; Einsele H
    Haematologica; 2023 Apr; 108(4):958-968. PubMed ID: 36263838
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Antibody Drug Conjugates in Multiple Myeloma.
    Ferreri CJ; Lee HC
    Cancer J; 2022 Nov-Dec 01; 28(6):488-495. PubMed ID: 36383912
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Real-World Data on Therapies for Relapsed or Refractory Multiple Myeloma: Key Data from ASH 2023-A Podcast.
    Costa LJ; Rodriguez-Otero P
    Adv Ther; 2024 Aug; 41(8):3017-3027. PubMed ID: 38642197
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Development and prospects of bispecific antibodies for multiple myeloma].
    Yuda J
    Rinsho Ketsueki; 2024; 65(9):1049-1057. PubMed ID: 39358260
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 45.